Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing

Journal of Virology

Volumn 82, Issue 13, 2008, Pages 6524-6535

  Dumortier, Jerome ^b   Streblow, Daniel N ^b   Moses, Ashlee V ^b   Jacobs, Jon M ^d   Kreklywich, Craig N ^b   Camp, David ^d   Smith, Richard D ^d   Orloff, Susan L ^a,b,c   Nelson, Jay A ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; TRANSCRIPTOME;

ANGIOGENESIS; ARTERIOSCLEROSIS; ARTICLE; CELL SURVIVAL; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART TRANSPLANTATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOASSAY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SUPERNATANT; TRANSPLANT VASCULAR SCLEROSIS; UNINDEXED SEQUENCE; VIRUS CELL INTERACTION; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; BODILY SECRETIONS; CELL LINE; CENTRIFUGATION; CYTOKINES; CYTOMEGALOVIRUS; FIBROBLASTS; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; WOUND HEALING;

HUMAN HERPESVIRUS 5; SIMPLEXVIRUS;

EID: 45749127856     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00502-08     Document Type: Article

References (48)

1. Billingham, M. E. 1992. Histopathology of graft coronary disease. J. Heart Lung Transplant. 11:S38-S44.
2. Bouis, D., Y. Kusumanto, C. Meijer, N. H. Mulder, and G. A. Hospers. 2006. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol. Res. 53:89-103.
3. Bruning, J. H., M. C. J. Persoons, K. B. Lemstrom, F. S. Stals, E. De Clereq, and C. A. Bruggeman. 1994. Enhancement of transplantation associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC. Transplant. Int. 7:365-370.
4. Carmeliet, P. 2003. Angiogenesis in health and disease. Nat. Med. 9:653-660.
5. Charrier, L., Y. Yan, A. Driss, C. L. Laboisse, S. V. Sitaraman, and D. Merlin. 2005. ADAM-15 inhibits wound healing in human intestinal epithelial cell monolayers. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G346-G353.
6. Clinton, S. K., and P. Libby. 1992. Cytokines and growth factors in atherogenesis. Arch. Pathol. Lab. Med. 116:1292-1300.
7. Donovan, D., N. J. Brown, E. T. Bishop, and C. E. Lewis. 2001. Comparison of three in vitro human "angiogenesis" assays with capillaries formed in vivo. Angiogenesis 4:113-121.
8. Eng, J., A. L. McCormack, and J. R. Yates. 1994. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5:976-989.
9. Fitzgerald, J. T., B. Gallay, S. E. Tarante, J. P. McVicar, C. Troppmann, X. Chen, M. J. Mcintosh, and R. V. Perez. 2004. Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival. Transplantation 77:1405-1411.
10. Folkman, J. 2003. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3:643-651.
11. Grattan, M. T., C. E. Moreno-Cabral, V. A. Starnes, P. E. Oyer, E. B. Stinson, and N. E. Shumway. 1989. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261: 3561-3566.
12. Hosenpud, J. D., G. D. Shipley, and C. R. Wagner. 1992. Cardiac allograft vasculopathy: current concepts, recent developments and future directions. J. Heart Lung Transplant. 11:9-23.
13. Inkinen, K., K. Holma, A. Soots, L. Krogerus, R. Loginov, C. Bruggeman, J. Ahonen, and I. Lautenschlager. 2003. Expression of TGF-beta and PDGF-AA antigens and corresponding mRNAs in cytomegalovirus-infected rat kidney allografts. Transplant. Proc. 35:804-805.
14. Inkinen, K., R. Lahesmaa, A. Brandt, M. Katajamaa, L. Halme, K. Hockerstedt, and I. Lautenschlager. 2005. DNA microarray-based gene expression profiles of cytomegalovirus infection and acute rejection in liver transplants. Transplant. Proc. 37:1227-1229.
15. Keese, C. R., J. Wegener, S. R. Walker, and I. Giaever. 2004. Electrical wound-healing assay for cells in vitro. Proc. Natl. Acad. Sci. USA 101:1554-1559.
16. Kent, D., and C. Sheridan. 2003. Choroidal neovascularization: a wound healing perspective. Mol. Vis. 9:747-755.
17. Khurana, R., and M. Simons. 2003. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc. Med. 13:116-122.
18. Lemstrom, K., P. Koskinen, L. Krogerus, M. Daemen, C. A. Bruggeman, and P. J. Hayry. 1995. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 92:2594-2604.
19. Lemstrom, K. B., J. H. Bruning, C. A. Bruggeman, I. T. Lautenschlager, and P. J. Hayry. 1993. Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts. J. Clin. Investig. 92:549-558.
20. Lemstrom, K. B., and P. K. Koskinen. 1997. Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allografts. Circulation 96:1240-1249.
21. Libby, P., P. M. Ridker, and A. Maseri. 2002. Inflammation and atherosclerosis. Circulation 105:1135-1143.
22. Libby, P., R. N. Salomon, D. D. Payne, F. J. Schoen, and J. S. Pober. 1989. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant. Proc. 21:3677-3684.
23. Melnick, J. L., E. Adam, and M. E. DeBakey. 1998. The link between CMV and atherosclerosis. Infect. Med. 15:479-486.
24. Melnick, J. L., B. L. Petrie, G. R. Dreesman, J. Burek, C. H. McCollum, and M. E. DeBakey. 1983. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 322:644-647.
25. Merigan, T. C., D. G. Renlund, S. Keay, et al. 1992. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med. 326:1182-1186.
26. Nesvizhskii, A. I., A. Keller, E. Kolker, and R. Aebersold. 2003. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75:4646-4658.
27. Noda, S., S. A. Aguirre, A. Bitmansour, J. M. Brown, T. E. Sparer, J. Huang, and E. S. Mocarski. 2006. Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. Blood 107:30-38.
28. Orloff, S. L. 1999. Elimination of donor-specific alloreactivity by bone marrow chimerism prevents cytomegalovirus accelerated transplant vascular sclerosis in rat small bowel transplants. J. Clin. Virol. 12:142.
29. Orloff, S. L., D. N. Streblow, C. Soderberg-Naucler, Q. Yin, C. Kreklywich, C. L. Corless, P. A. Smith, C. B. Loomis, L. K. Mills, J. W. Cook, C. A. Bruggeman, J. A. Nelson, and C. R. Wagner. 2002. Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants. Transplantation 73:679-688.
30. Orloff, S. L., Q. Yin, C. L. Corless, M. S. Orloff, J. M. Rabkin, and C. R. Wagner. 2000. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection. Transplantation 69:1295-1303.
31. Oyabu, J., Y. Ueda, N. Ogasawara, K. Okada, A. Hirayama, and K. Kodama. 2006. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. Am. Heart J. 152:1168-1174.
32. Qian, W. J., T. Liu, M. E. Monroe, E. F. Strittmatter, J. M. Jacobs, L. J. Kangas, K. Petritis, D. G. Camp II, and R. D. Smith. 2005. Probability-based evaluation of peptide and protein identifications from tandem mass spectrometry and SEQUEST analysis: the human proteome. J. Proteome Res. 4:53-62.
33. Reinhardt, B., P. Schaarschmidt, A. Bessert, A. Luske, G. Finkenzeller, T. Mertens, and D. Michel. 2005. Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus. J. Gen. Virol. 86:23-30.
34. Shibata, M., H. Suzuki, M. Nakatani, S. Koba, E. Geshi, T. Katagiri, and Y. Takeyama. 2001. The involvement of vascular endothelial growth factor and flt-1 in the process of neointimal proliferation in pig coronary arteries following stent implantation. Histochem. Cell Biol. 116:471-481.
35. Soule, J. L., D. N. Streblow, T. F. Andoh, C. N. Kreklywich, and S. L. Orloff. 2006. Cytomegalovirus accelerates chronic allograft nephropathy in a rat renal transplant model with associated provocative chemokine profiles. Transplant. Proc. 38:3214-3220.
36. Sparer, T. E., J. Gosling, T. J. Schall, and E. S. Mocarski. 2004. Expression of human CXCR2 in murine neutrophils as a model for assessing cytomegalovirus chemokine vCXCL-1 function in vivo. J. Interferon Cytokine Res. 24:611-620.
37. Speir, E., R. Modali, E. S. Huang, M. B. Leon, F. Shawl, T. Finkel, and S. E. Epstein. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394.
38. Streblow, D. N., C. Kreklywich, Q. Yin, V. T. De La Melena, C. L. Corless, P. A. Smith, C. Brakebill, J. W. Cook, C. Vink, C. A. Bruggeman, J. A. Nelson, and S. L. Orloff. 2003. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J. Virol. 77:2182-2194.
39. Streblow, D. N., C. N. Kreklywich, T. Andoh, A. V. Moses, J. Dumortier, P. P. Smith, V. Defilippis, K. Fruh, J. A. Nelson, and S. L. Orloff. 2008. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am. J. Transplant. 8:277-287.
40. Suzuki, S., H. Kamihata, T. Hata, F. Hayashi, A. Miura, M. Yoshinaga, M. Karakawa, and Y. Kitaura. 2007. Success rate of implantation and mid-term outcomes of the sirolimus-eluting stent. Circ. J. 71:15-19.
41. Thuesen, L., H. Kelbaek, L. Klovgaard, S. Helqvist, E. Jorgensen, S. Aljabbari, L. R. Krusell, G. V. Jensen, H. E. Botker, K. Saunamaki, J. F. Lassen, and A. van Weert. 2006. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). Am. Heart J. 152:1140-1145.
42. Tikkanen, J., E. Kallio, V. Pulkkinen, C. Bruggeman, P. Koskinen, and K. Lemstrom. 2001. Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis. Transplant. Proc. 33:1801.
43. Tikkanen, J. M., E. A. Kallio, C. A. Bruggeman, P. K. Koskinen, and K. B. Lemstrom. 2001. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am. J. Respir. Crit. Care Med. 164:672-679.
44. Valantine, H. A., S. Z. Gao, G. Santosh, et al. 1999. Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis. A post-hoc analysis of a randomized, placebo-controlled study. Circulation 100:61-66.
45. Wentworth, B. B., and L. French. 1970. Plaque assay of cytomegalovirus strains of human origin. Proc. Soc. Exp. Biol. Med. 135:253-258.
46. Werner, S., and R. Grose. 2003. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83:835-870.
47. Wu, T. C., R. H. Hruban, R. F. Ambinder, M. Pizzorno, D. E. Cameron, W. A. Baumgartner, B. A. Reitz, G. S. Hayward, and G. M. Hutchins. 1992. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am. J. Pathol. 140:739-747.
48. Zeng, H., W. J. Waldman, D. P. Yin, D. A. Knight, J. Shen, L. Ma, G. T. Meister, A. S. Chong, and J. W. Williams. 2005. Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats. Transplantation 79:17-22.